Two Sigma Advisers
FUSN

Two Sigma Advisers’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Two Sigma Advisers’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,700
Closed -$249K – 2740
2024
Q1 		$249K Buy
11,700
+200
+2% +$2.39K ﹤0.01% 2136
2023
Q4 		$111K Sell
11,500
-20,600
-64% -$100K ﹤0.01% 2317
2023
Q3 		$83.5K Sell
32,100
-33,300
-51% -$107K ﹤0.01% 2232
2023
Q2 		$305K Buy
65,400
+29,500
+82% +$128K ﹤0.01% 1977
2023
Q1 		$135K Buy
+35,900
New +$141K ﹤0.01% 2335

Two Sigma Advisers's FUSN Position: Q2 2024 in Review

Two Sigma Advisers sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 11,700 shares — an estimated $249K sold.

Two Sigma Advisers first reported a position in FUSN in Q1 2023 and held it in 5 quarters. The position peaked at $305K in Q2 2023. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.

  • Two Sigma Advisers reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 11,700 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $249K.
  • Two Sigma Advisers first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q1 2023 and held it in 5 quarters.
  • Two Sigma Advisers's Fusion Pharmaceuticals Inc. Common Shares position peaked at $305K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.

Based on Two Sigma Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.